Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Effects of chondroitin sulfate on brain response to painful stimulation in knee osteoarthritis patients. A randomized, double-blind, placebo-controlled functional magnetic resonance imaging study

  • Monfort Faure, Jorge
  • Pujol Nuez, Jesús
  • Contreras-Rodríguez, O.
  • Llorente-Onaindia, J.
  • López-Solà, Marina
  • Blanco Hinojo, Laura, 1981-
  • Vergés, Josep
  • Herrero, Marta
  • Sánchez, Laura
  • Ortiz, Héctor
  • Montañés, F.
  • Deus, Joan
  • Benito Ruiz, Pedro
INTRODUCTION: Knee osteoarthritis is causing pain and functional disability. One of the inherent problems with efficacy assessment of pain medication was the lack of objective pain measurements, but functional magnetic resonance imaging (fMRI) has emerged as a useful means to objectify brain response to painful stimulation. We have investigated the effect of chondroitin sulfate (CS) on brain response to knee painful stimulation in patients with knee osteoarthritis using fMRI. METHODS: Twenty-two patients received CS (800mg/day) and 27 patients placebo, and were assessed at baseline and after 4 months of treatment. Two fMRI tests were conducted in each session by applying painful pressure on the knee interline and on the patella surface. The outcome measurement was attenuation of the response evoked by knee painful stimulation in the brain. RESULTS: fMRI of patella pain showed significantly greater activation reduction under CS compared with placebo in the region of the mesencephalic periaquecductal gray. The CS group, additionally showed pre/post-treatment activation reduction in the cortical representation of the leg. No effects of CS were detected using the interline pressure test. CONCLUSIONS: fMRI was sensitive to objectify CS effects on brain response to painful pressure on patellofemoral cartilage, which is consistent with the known CS action on chondrocyte regeneration. The current work yields further support to the utility of fMRI to objectify treatment effects on osteoarthritis pain., This work was supported in part by the Ministry of Science and Innovation of Spain (Grant SAF2010-19434) and by Bioiberica, SA, Barcelona. M. López-Solà and J. Deus are part of the Research Group SGR 1450 from the Agency of University and Research Funding Management of the Catalan Government and M. López-Solà is supported by the post-doctoral fellowship Beatriu de Pinós awarded by the Agency for the Management of University and Research funding (Agència de Gestió d’Ajuts Universitaris i de Recerca; AGAUR), from the Catalan Government (2010 BP_A 00136).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease

  • Xicota Vila, Laura, 1987-
  • Rodríguez-Morató, Jose, 1987-
  • Dierssen, Mara
  • Torre Fornell, Rafael de la
Medical advances in the last decades have increased the average life expectancy, but also the incidence and prevalence of age-associated neurodegenerative diseases. Alzheimer's disease (AD) is one of the most common neurodegenerative diseases and the most prevalent type of dementia. A plethora of different mechanisms contribute to AD, among which oxidative stress plays a key role in its development and progression. So far, there are no pharmacological treatments available and the current medications are mainly symptomatic. In the last years, dietary polyphenols have gained research attention due to their interesting biological activities, and more specifically their antioxidant properties. (-)- Epigallocatechin-3-gallate (EGCG) is a natural flavanol that has been extensively studied regarding its potential effects in AD. In this review we present the current in vitro and in vivo experimentation regarding the use of EGCG in AD. We also review the complex mechanisms of action of EGCG, not only limited to its antioxidant activity, which may explain its beneficial health effects., This work was supported by grants, donations and agreements from Fondation Jérôme Lejeune (Paris, France), Instituto de Salud Carlos III FEDER, (PI11/00744), MINECO (SAF2010- 19434, MTM2012-38067-C02-01 and SAF2013-49129-C1- R), EU (Era Net Neuron PCIN-2013-060) co-financed by European Regional Development Fund, DIUE de la Generalitat de Catalunya (SGR 2009/1450, SGR 2014/464 SGR 2014/1125). We acknowledge support of the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208.Jose Rodríguez-Morató was supported by a FI-DGR 2013 predoctoral fellowship from the Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma Aβ42 Concentrations in Down Syndrome Young Adults.

  • Del Hoyo Soriano, Laura
  • Xicota Vila, Laura, 1987-
  • Sánchez Benavides, Gonzalo
  • Cuenca Royo, Aida Ma, 1981-
  • Sola Llopis, Susana de
  • Langohr, Klaus
  • Fagundo, Ana B.
  • Farré Albaladejo, Magí
  • Dierssen, Mara
  • Torre Fornell, Rafael de la
Down syndrome (DS) is an intellectual disability (ID) disorder in which language and specifically, verbal fluency are strongly impaired domains; nearly all adults show neuropathology of Alzheimer's disease (AD), including amyloid deposition by their fifth decade of life. In the general population, verbal fluency deficits are considered a strong AD predictor being the semantic verbal fluency task (SVFT) a useful tool for enhancing early diagnostic. However, there is a lack of information about the association between the semantic verbal fluency pattern (SVFP) and the biological amyloidosis markers in DS. In the current study, we used the SVFT in young adults with DS to characterize their SVFP, assessing total generated words, clustering, and switching. We then explored its association with early indicators of dementia, adaptive behavior and amyloidosis biomarkers, using the Dementia Questionnaire for Persons with Intellectual Disability (DMR), the Adaptive Behavior Assessment System-Second Edition (ABAS-II), and plasma levels of Aβ peptides (Aβ40 and Aβ42), as a potent biomarker of AD. In DS, worse performance in SVFT and poorer communication skills were associated with higher plasma Aβ42 concentrations, a higher DMR score and impaired communication skills (ABAS-II). The total word production and switching ability in SVFT were good indicators of plasma Aβ42 concentration. In conclusion, we propose the SVFT as a good screening test for early detection of dementia and amyloidosis in young adults with DS., This work was supported by grants, donations and agreements from Fondation Jérôme Lejeune (Paris, France), Instituto de Salud Carlos III FEDER, (PI11/00744), MINECO (SAF2010-19434 and SAF2013-49129-C2-1-R), EU (Era Net Neuron PCIN-2013-060), DIUE de la Generalitat de Catalunya (SGR 2009/1450 and SGR 2009/718).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Effects of chondroitin sulfate on brain response to painful stimulation in knee osteoarthritis patients. A randomized, double-blind, placebo-controlled functional magnetic resonance imaging study

  • Monfort Faure, Jorge
  • Pujol Nuez, Jesús
  • Contreras-Rodríguez, O.
  • Llorente-Onaindia, J.
  • López-Solà, Marina
  • Blanco Hinojo, Laura, 1981-
  • Vergés, Josep
  • Herrero, Marta
  • Sánchez, Laura
  • Ortiz, Héctor
  • Montañés, F.
  • Deus, Joan
  • Benito Ruiz, Pedro
INTRODUCTION: Knee osteoarthritis is causing pain and functional disability. One of the inherent problems with efficacy assessment of pain medication was the lack of objective pain measurements, but functional magnetic resonance imaging (fMRI) has emerged as a useful means to objectify brain response to painful stimulation. We have investigated the effect of chondroitin sulfate (CS) on brain response to knee painful stimulation in patients with knee osteoarthritis using fMRI. METHODS: Twenty-two patients received CS (800mg/day) and 27 patients placebo, and were assessed at baseline and after 4 months of treatment. Two fMRI tests were conducted in each session by applying painful pressure on the knee interline and on the patella surface. The outcome measurement was attenuation of the response evoked by knee painful stimulation in the brain. RESULTS: fMRI of patella pain showed significantly greater activation reduction under CS compared with placebo in the region of the mesencephalic periaquecductal gray. The CS group, additionally showed pre/post-treatment activation reduction in the cortical representation of the leg. No effects of CS were detected using the interline pressure test. CONCLUSIONS: fMRI was sensitive to objectify CS effects on brain response to painful pressure on patellofemoral cartilage, which is consistent with the known CS action on chondrocyte regeneration. The current work yields further support to the utility of fMRI to objectify treatment effects on osteoarthritis pain., This work was supported in part by the Ministry of Science and Innovation of Spain (Grant SAF2010-19434) and by Bioiberica, SA, Barcelona. M. López-Solà and J. Deus are part of the Research Group SGR 1450 from the Agency of University and Research Funding Management of the Catalan Government and M. López-Solà is supported by the post-doctoral fellowship Beatriu de Pinós awarded by the Agency for the Management of University and Research funding (Agència de Gestió d’Ajuts Universitaris i de Recerca; AGAUR), from the Catalan Government (2010 BP_A 00136).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma Aβ42 Concentrations in Down Syndrome Young Adults.

  • Del Hoyo Soriano, Laura
  • Xicota Vila, Laura, 1987-
  • Sánchez Benavides, Gonzalo
  • Cuenca Royo, Aida Ma, 1981-
  • Sola Llopis, Susana de
  • Langohr, Klaus
  • Fagundo, Ana B.
  • Farré Albaladejo, Magí
  • Dierssen, Mara
  • Torre Fornell, Rafael de la
Down syndrome (DS) is an intellectual disability (ID) disorder in which language and specifically, verbal fluency are strongly impaired domains; nearly all adults show neuropathology of Alzheimer's disease (AD), including amyloid deposition by their fifth decade of life. In the general population, verbal fluency deficits are considered a strong AD predictor being the semantic verbal fluency task (SVFT) a useful tool for enhancing early diagnostic. However, there is a lack of information about the association between the semantic verbal fluency pattern (SVFP) and the biological amyloidosis markers in DS. In the current study, we used the SVFT in young adults with DS to characterize their SVFP, assessing total generated words, clustering, and switching. We then explored its association with early indicators of dementia, adaptive behavior and amyloidosis biomarkers, using the Dementia Questionnaire for Persons with Intellectual Disability (DMR), the Adaptive Behavior Assessment System-Second Edition (ABAS-II), and plasma levels of Aβ peptides (Aβ40 and Aβ42), as a potent biomarker of AD. In DS, worse performance in SVFT and poorer communication skills were associated with higher plasma Aβ42 concentrations, a higher DMR score and impaired communication skills (ABAS-II). The total word production and switching ability in SVFT were good indicators of plasma Aβ42 concentration. In conclusion, we propose the SVFT as a good screening test for early detection of dementia and amyloidosis in young adults with DS., This work was supported by grants, donations and agreements from Fondation Jérôme Lejeune (Paris, France), Instituto de Salud Carlos III FEDER, (PI11/00744), MINECO (SAF2010-19434 and SAF2013-49129-C2-1-R), EU (Era Net Neuron PCIN-2013-060), DIUE de la Generalitat de Catalunya (SGR 2009/1450 and SGR 2009/718).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease

  • Xicota Vila, Laura, 1987-
  • Rodríguez-Morató, Jose, 1987-
  • Dierssen, Mara
  • Torre Fornell, Rafael de la
Medical advances in the last decades have increased the average life expectancy, but also the incidence and prevalence of age-associated neurodegenerative diseases. Alzheimer's disease (AD) is one of the most common neurodegenerative diseases and the most prevalent type of dementia. A plethora of different mechanisms contribute to AD, among which oxidative stress plays a key role in its development and progression. So far, there are no pharmacological treatments available and the current medications are mainly symptomatic. In the last years, dietary polyphenols have gained research attention due to their interesting biological activities, and more specifically their antioxidant properties. (-)- Epigallocatechin-3-gallate (EGCG) is a natural flavanol that has been extensively studied regarding its potential effects in AD. In this review we present the current in vitro and in vivo experimentation regarding the use of EGCG in AD. We also review the complex mechanisms of action of EGCG, not only limited to its antioxidant activity, which may explain its beneficial health effects., This work was supported by grants, donations and agreements from Fondation Jérôme Lejeune (Paris, France), Instituto de Salud Carlos III FEDER, (PI11/00744), MINECO (SAF2010- 19434, MTM2012-38067-C02-01 and SAF2013-49129-C1- R), EU (Era Net Neuron PCIN-2013-060) co-financed by European Regional Development Fund, DIUE de la Generalitat de Catalunya (SGR 2009/1450, SGR 2014/464 SGR 2014/1125). We acknowledge support of the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208.Jose Rodríguez-Morató was supported by a FI-DGR 2013 predoctoral fellowship from the Generalitat de Catalunya.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

VNTR-DAT1 and COMTVal158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome

  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Xicota, Laura|||0000-0003-2832-9214
  • Langohr, Klaus|||0000-0001-7075-9192
  • Sánchez Benavides, Gonzalo
  • de Sola, Susana
  • Cuenca-Royo, Aida|||0000-0001-8551-5457
  • Rodríguez Soler, Joan|||0000-0003-0062-6401
  • Rodríguez-Morató, Jose|||0000-0002-8133-9983
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Dierssen, Mara|||0000-0003-0853-6865
  • Torre, Rafael de la|||0000-0002-6765-1866
Down syndrome (DS) is an aneuploidy syndrome that is caused by trisomy for human chromosome 21 resulting in a characteristic cognitive and behavioral phenotype, which includes executive functioning and adaptive behavior difficulties possibly due to prefrontal cortex (PFC) deficits. DS also present a high risk for early onset of Alzheimer Disease-like dementia. The dopamine (DA) system plays a neuromodulatory role in the activity of the PFC. Several studies have implicated trait differences in DA signaling on executive functioning based on genetic polymorphisms in the genes encoding for the catechol-O-methyltransferase (COMTVal158Met) and the dopamine transporter (VNTR-DAT1). Since it is known that the phenotypic consequences of genetic variants are modulated by the genetic background in which they occur, we here explore whether these polymorphisms variants interact with the trisomic genetic background to influence gene expression, and how this in turn mediates DS phenotype variability regarding PFC cognition. We genotyped 69 young adults of both genders with DS, and found that VNTR-DAT1 was in Hardy-Weinberg equilibrium but COMTVal158Met had a reduced frequency of Met allele homozygotes. In our population, genotypes conferring higher DA availability, such as Met allele carriers and VNTR-DAT1 10-repeat allele homozygotes, resulted in improved performance in executive function tasks that require mental flexibility. Met allele carriers showed worse adaptive social skills and self-direction, and increased scores in the social subscale of the Dementia Questionnaire for People with Intellectual Disabilities than Val allele homozygotes. The VNTR-DAT1 was not involved in adaptive behavior or early dementia symptoms. Our results suggest that genetic variants of COMTVal158Met and VNTR-DAT1 may contribute to PFC-dependent cognition, while only COMTVal158Met is involved in behavioral phenotypes of DS, similar to euploid population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma Aβ Concentrations in Down Syndrome Young Adults

  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Xicota, Laura|||0000-0003-2832-9214
  • Sánchez Benavides, Gonzalo
  • Cuenca-Royo, Aida|||0000-0001-8551-5457
  • de Sola, Susana
  • Langohr, Klaus|||0000-0001-7075-9192
  • Fagundo, Ana Beatriz|||0000-0003-1703-9457
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Dierssen, Mara|||0000-0003-0853-6865
  • Torre, Rafael de la|||0000-0002-6765-1866
Down syndrome (DS) is an intellectual disability (ID) disorder in which language and specifically, verbal fluency are strongly impaired domains; nearly all adults show neuropathology of Alzheimer's disease (AD), including amyloid deposition by their fifth decade of life. In the general population, verbal fluency deficits are considered a strong AD predictor being the semantic verbal fluency task (SVFT) a useful tool for enhancing early diagnostic. However, there is a lack of information about the association between the semantic verbal fluency pattern (SVFP) and the biological amyloidosis markers in DS. In the current study, we used the SVFT in young adults with DS to characterize their SVFP, assessing total generated words, clustering, and switching. We then explored its association with early indicators of dementia, adaptive behavior and amyloidosis biomarkers, using the Dementia Questionnaire for Persons with Intellectual Disability (DMR), the Adaptive Behavior Assessment System-Second Edition (ABAS-II), and plasma levels of Aβ peptides (Aβ and Aβ), as a potent biomarker of AD. In DS, worse performance in SVFT and poorer communication skills were associated with higher plasma Aβ concentrations, a higher DMR score and impaired communication skills (ABAS-II). The total word production and switching ability in SVFT were good indicators of plasma Aβ concentration. In conclusion, we propose the SVFT as a good screening test for early detection of dementia and amyloidosis in young adults with DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The neurologic pain signature responds to nonsteroidal anti-inflammatory treatment vs placebo in knee osteoarthritis

  • López-Solà, Marina|||0000-0002-5517-2665
  • Pujol Nuez, Jesús|||0000-0002-9946-4547
  • Monfort, Jordi|||0000-0002-9103-661X
  • Deus Yela, Juan|||0000-0002-3305-2662
  • Blanco Hinojo, Laura, 1981-
  • Harrison, Ben J.
  • Wager, Tor D.|||0000-0002-1936-5574
Supplemental Digital Content is Available in the Text. fMRI-based measures, validated for nociceptive pain, respond to acute osteoarthritis pain, are not sensitive to placebo, and are mild-to-moderately sensitive to naproxen. Many drug trials for chronic pain fail because of high placebo response rates in primary endpoints. Neurophysiological measures can help identify pain-linked pathophysiology and treatment mechanisms. They can also help guide early stop/go decisions, particularly if they respond to verum treatment but not placebo. The neurologic pain signature (NPS), an fMRI-based measure that tracks evoked pain in 40 published samples and is insensitive to placebo in healthy adults, provides a potentially useful neurophysiological measure linked to nociceptive pain. This study aims to validate the NPS in knee osteoarthritis (OA) patients and test the effects of naproxen on this signature. In 2 studies (50 patients, 64.6 years, 75% females), we (1) test the NPS and other control signatures related to negative emotion in knee OA pain patients; (2) test the effect of placebo treatments; and (3) test the effect of naproxen, a routinely prescribed nonsteroidal anti-inflammatory drug in OA. The NPS was activated during knee pain in OA (d = 1.51, P < 0.001) and did not respond to placebo (d = 0.12, P = 0.23). A single dose of naproxen reduced NPS responses (vs placebo, NPS d = 0.34, P = 0.03 and pronociceptive NPS component d = 0.38, P = 0.02). Naproxen effects were specific for the NPS and did not appear in other control signatures. This study provides preliminary evidence that fMRI-based measures, validated for nociceptive pain, respond to acute OA pain, do not appear sensitive to placebo, and are mild-to-moderately sensitive to naproxen.